Schedule 13G ownership disclosure

NEWAMSTERDAM PHARMA COMPANY

Ordinary Shares, nominal value EUR0.12 per share · CUSIP: N62509109

Event date: 2024-12-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • VIKING GLOBAL INVESTORS LP

    Shares: 6,978,534 · Class: 6.5%

  • Viking Global Opportunities Parent GP LLC

    Shares: 6,978,534 · Class: 6.5%

  • Viking Global Opportunities GP LLC

    Shares: 4,675,619 · Class: 4.4%

  • Viking Global Opportunities Portfolio GP LLC

    Shares: 4,675,619 · Class: 4.4%

  • Viking Global Opportunities Illiquid Investments Sub-Master LP

    Shares: 4,675,619 · Class: 4.4%

  • Viking Global Opportunities Drawdown GP LLC

    Shares: 2,302,915 · Class: 2.2%

  • Viking Global Opportunities Drawdown Portfolio GP LLC

    Shares: 2,302,915 · Class: 2.2%

  • Viking Global Opportunities Drawdown (Aggregator) LP

    Shares: 2,302,915 · Class: 2.2%

  • HALVORSEN OLE ANDREAS

    Shares: 6,978,534 · Class: 6.5%

  • Ott David C.

    Shares: 6,978,534 · Class: 6.5%

  • Shabet Rose Sharon

    Shares: 6,978,534 · Class: 6.5%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000905148-25-000679
Form type
SCHEDULE 13G/A
Filer
NewAmsterdam Pharma Co N.V.
CIK
CIK 1936258
Filed
Feb 14, 2025
Reporting period
Dec 31, 2024
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub